看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
2 Z* N/ B. v+ C: G# H) @; J) t7 l. W! o
B+ a8 U5 p) X0 D. g
Currently available feasibility data for possible combination strategies. + c% |5 f- b0 P1 h9 S! H4 j
————————————————————————————————0 P1 v+ j3 B, U2 i4 y/ t! B% A
Combination Feasibility according to preliminary data / Q7 G) P8 h2 s, g: e
——————————————————————————————————
4 B7 t2 |8 g% q8 M$ c kBevacizumab + sorafenib Yes, reduced dose 6 d3 ~* \% E. ^. H0 u6 `* v
Bevacizumab + sunitinib† No , Y" ~/ W. `. Q% E# Z6 d
Bevacizumab + temsirolimus Yes
9 T& k; u' K& \+ |9 F, ]' p6 ]3 \Bevacizumab + everolimus Yes 5 E2 y. v8 Q! y% h- Z8 q& r% E( r
Sorafenib + sunitinib ? ( M* q2 r+ q& O. k$ _4 `! E
Sorafenib + temsirolimus Yes, reduced dose
k$ G' B& U% k! P+ W4 iSorafenib + everolimus Yes, reduced dose 8 H4 Q6 F( ?* k h$ X
Sunitinib + temsirolimus† No
* T/ x. l! C8 P Z1 {/ wSunitinib + everolimus ? , K2 }7 {$ }) h, ]& w) }) T
Temsirolimus + everolimus ? 5 A# X4 l/ l* S2 N% }6 `
————————————————————) ]; w% t0 F( H5 ~3 l) z. B
†Led to US FDA warning.& z' }$ H. m8 d8 a0 k% L, [, c
?: As yet unattempted combination.! [! W8 B. X5 L/ e$ \
|